| Ident. | Authors (with country if any) | Title |
|---|
| 002048 (1997) |
B. Dubois ; Bernard Pillon | Cognitive deficits in Parkinson’s disease |
| 002151 (1996) |
F. Tison [France] ; K. Wenning [Autriche] ; A. Volonte [Italie] ; R. Poewe [Autriche] ; P. Henry [France] ; P. Quinn [Royaume-Uni] | Pain in multiple system atrophy |
| 002298 (1995) |
| Parkinson's disease |
| 002396 (1994) |
Mario Zappia [Italie] ; Rita Montesanti [Italie] ; Rosanna Colao [Italie] ; Aldo Quattrone [Italie] | Usefulness of movement time in the assessment of Parkinson's disease |
| 002454 (1994) |
Letizia Mazzini [Italie] ; Daniela Testa [Italie] ; Carla Balzarini [Italie] ; Gabriele Mora [Italie] | An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis |
| 002495 (1993) |
Peter Jenner [Royaume-Uni] | Maladie de Parkinson: mécanismes physiopathologiques et effets du piribédil |
| 002496 (1993) |
C. Corbe [France] ; F. Arnaud [France] ; Y. Brault [France] ; C. Janiak-Bolzinger [France] | Effet d'un agoniste dopaminergique, le piribédil (Trivastal 50 mg LP) sur l'intégration visuelle spatiale du sujet âgé |
| 002497 (1993) |
B. Dubois [France] ; B. Pillon [France] ; Yves Agid [France] | Détérioration des voies dopaminergiques et altérations des fonctions cognitives et motrices |
| 002498 (1993) |
P. Rondot [France] ; M. Ziegler [France] | Activité et acceptabilité du piribédil dans la maladie de Parkinson: étude multicentrique |
| 002620 (1992) |
Peter Jenner [Royaume-Uni] | Parkinson's disease: pathological mechanisms and actions of piribedil |
| 002633 (1992) |
L. Angelini [Italie] ; N. Nardocci [Italie] ; V. Rumi [Italie] ; C. Zorzi [Italie] ; L. Strada [Italie] ; M. Savoiardo [Italie] | Hallervorden-Spatz disease: clinical and MRI study of 11 cases diagnosed in life |
| 002636 (1992) |
C. Corbe [France] ; F. Arnaud [France] ; Y. Brault [France] ; C. Janiak-Bolzinger [France] | Effect of a dopaminergic agonist, piribedil (Trivastal 50 mg LP), on visual and spatial integration in elderly subjects |
| 002650 (1992) |
P. Rondot [France] ; M. Ziegler [France] | Activity and acceptability of piribedil in Parkinson's disease: a multicentre study |
| 002688 (1991) |
G. Bellomo [Italie] ; L. Santambrogio [Italie] ; M. Fiacconi [Italie] ; M. Scarponi [Italie] ; G. Ciuffetti [Italie] | Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated parkinson's disease |
| 002717 (1991) |
Giuseppe Meco [Italie] ; Luca Pratesi [Italie] ; Vincenzo Bonifati [Italie] | Cardiovascular reflexes and autonomic dysfunction in parkinson's disease |
| 002718 (1991) |
S. Compston [Royaume-Uni] | Book review — James Parkinson: his life and times by A. D. Morris |
| 002757 (1990) |
G. Goldenberg [Autriche] | Performance of concurrent non-motor tasks in parkinson's disease |
| 002778 (1990) |
K. Kosaka [Japon] | Diffuse lewy body disease in Japan |
| 002815 (1989) |
F. Boomsma [Pays-Bas] ; D. Meerwaldt [Pays-Bas] ; J. Man In'T Veld [Pays-Bas] ; A. Hovestadt [Pays-Bas] ; H. Schalekamp [Pays-Bas] | Treatment of idiopathic parkinsonism with l -dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of l -dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa |
| 002832 (1989) |
M. Ludin [Suisse] ; P. Ludin [Suisse] | Is Parkinson's disease of early onset a separate disease entity? |
| 002845 (1989) |
M. Brenner [Allemagne] ; A. Haass [Allemagne] ; P. Jacobi [Allemagne] ; K. Schimrigk [Allemagne] | Amantadine sulphate in treating Parkinson's disease: Clinical effects, psychometric tests and serum concentrations |
| 002912 (1987) |
G. Ransmayr [Autriche] ; B. Schmidhuber-Eiler [Autriche] ; E. Karamat [Autriche] ; S. Engler-Plörer [Autriche] ; Werner Poewe [Autriche] ; K. Leidlmair [Autriche] | Visuoperception and visuospatial and visuorotational performance in Parkinson's disease |
| 002928 (1987) |
S. Kosti [Yougoslavie] ; M. Djuri I [Yougoslavie] ; N. Ovi Kovi Terni [Yougoslavie] ; L. Bumbaširevi [Yougoslavie] ; M. Nikoli [Yougoslavie] ; B. Mršulja [Yougoslavie] | Depression and parkinson's disease: possible role of serotonergic mechanisms |
| 002939 (1987) |
Kurt Jellinger [Autriche] ; Harald Bliesath [Allemagne] | Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo |
| 002961 (1986) |
J. Ulrich [Suisse] ; A. Probst [Suisse] ; M. Wüest [Suisse] | The brain diseases causing senile dementia |
| 002A01 (1985) |
E. Schneider [Allemagne] ; H. Baas [Allemagne] ; P.-A. Fischer [Allemagne] ; G. Japp [Allemagne] | Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism |
| 002A47 (1984) |
P. Jeanty [Belgique] ; M. Van Den Kerchove [Belgique] ; A. Lowenthal [Belgique] ; H. De Bruyne [Belgique] | Pergolide therapy in parkinson's disease |
| 002A91 (1983) |
M. Yoshimura [Autriche, Japon] | Cortical changes in the parkinsonian brain: a contribution to the delineation of “diffuse Lewy body disease” |
| 002B18 (1982) |
E. Schneider [Allemagne] ; -A. Fischer [Allemagne] | Long-term experience with bromocriptine in advanced parkinsonism |
| 002B28 (1982) |
Kurt Jellinger [Autriche] | Adjuvant treatment of parkinson's disease with dopamine agonists: Open trial with bromocriptine and CU 32-085 |
| 002B71 (1980) |
G. Rosati [Italie] ; P. De Bastiani [Italie] ; P. Gilli [Italie] ; E. Paolino [Italie] | Oral aluminum and neuropsychological functioning |
| 002C03 (1978) |
J. Vardi [Israël] ; H. Glaubman [Israël] ; M. Rabey [Israël] ; M. Streifler [Israël] | Myoclonic attacks induced by L-Dopa and Bromocryptin in Parkinson patients |
| 002C11 (1978) |
Hiroshi Shibasaki [Japon] ; Fumio Shima [Japon] ; Yoshigoro Kuroiwa [Japon] | Clinical studies of the movement-related cortical potential (MP) and the relationship between the dentatorubrothalamic pathway and readiness potential (RP) |
| 002C27 (1977) |
J. Marttila [Finlande] ; K. Rinne [Finlande] ; T. Siirtola [Finlande] ; V. Sonninen [Finlande] | Mortality of patients with parkinson's disease treated with levodopa |
| 002C35 (1977) |
J. Wajsbort [Israël] | Zur Frage des Off-On-Effektes bei Levodopa-Behandlung des Parkinsonismus |
| 002C58 (1975) |
K. Rinne [Finlande] ; E. Birket-Smith [Danemark] ; E. Dupont [Danemark] ; E. Hansen [Danemark] ; M. Hyypp [Finlande] ; R. Marttila [Finlande] ; B. Mikkelsen [Danemark] ; H. Pakkenberg [Danemark] ; J. Presthus [Norvège] | Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (madopar®) in the treatment of Parkinson's disease |
| 002C93 (1972) |
K. Jellinger [Autriche] ; E. Neumayer [Autriche] | Unusual late-onset type of Hallervorden-Spatz disease |
| 002C94 (1972) |
K. Rinne [Finlande] ; V. Sonninen [Finlande] ; T. Siirtola [Finlande] | Treatment of Parkinson's disease with l -DOPA and decarboxylase inhibitor |
| 002D01 (1972) |
W. Birkmayer [Autriche] ; E. Neumayer [Autriche] | Die moderne medikamentöse Behandlung des Parkinsonismus |
| 002D03 (1972) |
E. Gründig [Autriche] ; F. Gerstenbrand [Autriche] ; J. Oberhummer [Autriche] ; M. Simanyi [Autriche] ; R. Schedl [Autriche] ; J. Weiss [Autriche] | Biochemische Aspekte der l-DOPA-Wirkung bei Parkinsonpatienten |
| 002D07 (1971) |
J. Chaco [Israël] ; O. Abramsky [Israël] | The effect of L-DOPA on postural reflexes in parkinson's disease |
| 002D14 (1971) |
E. Neumayer [Autriche] | Kombination von Morbus Parkinson mit anderen zentralnervösen Krankheiten |
| 002D25 (1969) |
E. Gründig [Allemagne] ; F. Gerstenbrand [Allemagne] ; J. Bruck [Allemagne] ; H. Gnad [Allemagne] ; P. Prosenz [Allemagne] ; R. Teuflmayr [Allemagne] | Der Einfluß der Verabreichung von Aminosäuren, speziell von L-Dopa und α-Methyldopa, auf die Zusammensetzung des Liquor cerebrospinalis bei extrapyramidalen Syndromen |
| 002D26 (1969) |
E. Gründig [Allemagne] ; F. Gerstenbrand [Allemagne] ; J. Bruck [Allemagne] ; H. Gnad [Allemagne] ; P. Prosenz [Allemagne] ; M. Simanyi [Allemagne] | Der Einfluß der Verabreichung von Aminosäuren, speziell von L-Dopa und α-Methyldopa, auf die Zusammensetzung des Liquor cerebrospinalis bei extrapyramidalen Syndromen |
